Tag Archives: DES

Esquema corto y monoterapia, una práctica llena de evidencia

Short Therapy and Monotherapy, Plenty of Evidence

Short Therapy and Monotherapy, Plenty of Evidence

A short dual antiplatelet therapy (DAPT) of 1 to 3 months followed by P2Y12 inhibitor monotherapy after second generation drug eluting stent (DES) implantation is safer and as effective as the traditional scheme. The idea is clear, but why hasn’t aspirin monotherapy been tested as follow up? Is aspirin old fashioned? Are there physiopathological reasons

DES con polímero bioabsorbible vs Bare Metal Stents en angioplastia primaria

Biodegradable Polymer Myth Also Debunked for ACSs

During TCT 2020 a preview of the results of the comparison of drug-eluting stents (DES) with biodegradable-polymer vs. durable-polymer in patients with acute coronary syndrome (ACS) was presented. The fine print and the final paper for HOST-REDUCE-POLYTECH-ACS are now published, and they lower the expectations set on biodegradable polymers. In patients with ACS undergoing angioplasty, biodegradable-polymer

DES con polímero bioabsorbible vs Bare Metal Stents en angioplastia primaria

Last Bastion of Bare Metal Stents Finally Falls

Multiple studies have shown the safety and efficacy of drug eluting stents (DES) in patients with high risk of bleeding. Only one last bastion of bare metal stents (BMS) was left standing: vein grafts.  With controversial evidence and different physiopathology, many still argued against DES in saphenous vein grafts.  This multicenter study randomized patients with

Desempeño de los DES actuales ¿hay margen para mejorar?

Current DES Performance: Is There Room for Improvement?

Head-to-head comparison of current drug-eluting stents (DES) showed contradictory results that led us to believe, for years, that we had reached a plateau. This feeling was also fostered by the disappointment caused by Absorb and bioresorbable-polymer stents. However, this recent article featured in JACC Interventions shows a light at the end of the tunnel with

El éxito de la angioplastia sobre las CTO por reestenosis disminuye la mortalidad cardíaca

In-Stent Restenosis Treatment: Meta-Analysis of 10 Randomized Studies

The best strategy to treat in stent restenosis continues to be a dilemma. A new drug eluting stent (DES) seems to be the simplest treatment, even though it adds metal layers that will make it harder and harder to retreat. Drug coated balloons might be a viable alternative seeing as it seems to enable retreatment,

TCT 2020 | Nueva información sobre el valor del FFR antes y después de la angioplastia

TCT 2020 | The Myth of Biodegradable Polymers Seems to Have Come to an End

This is the largest and newest study to compare drug eluting stents with durable polymers vs. biodegradable or bioresorbable polymers. As is usually the case, the theory clashes with reality.  The study has shown that the polymer does not seem to play an important role in the performance of drug eluting stents, or at least

¿Son los stents con polímero bioabsorbible más trombogénicos que los de segunda generación con polímero durable?

ISAR-TEST-5: 10 años de los DES con polímero vs sin polímero

After 10 years, unstable or chronic coronary patients revascularized with drug-eluting stents (DES) had similar, very good outcomes regardless of whether the DES did or did not have a polymer, according to the ISAR-TEST-5 study, recently published in J Am Coll Cardiol. The 10-year device-oriented endpoints occurred in 43.8% of patients treated with a polymer-free sirolimus-eluting

balon_farmacologico_reestenosis_instrastent

Two-Stent Strategy is Safer in True Bifurcation Lesions

Courtesy of Dr. Carlos Fava.  DES have improved PCI outcomes, but one of its biggest challenges continues to be bifurcations (especially when we have to use two stents, since it’s been associated to higher restenosis and stent thrombosis rates).  Left main coronary artery true bifurcation lesions are the ones that generate the greatest challenge and

Trombosis y riesgo de sangrado

Onyx ONE: More Options for Patients at High Risk for Bleeding

Since November 2015, when the LEADERS FREE was published in NEJM, polymer-free drug coated stents had undoubtedly been the best treatment for patients at high risk of bleeding. The benefit was owed to the safety and efficacy of the polymer-free biolimus coated stent (also called umirolimus) vs. bare metal stents in the context of just

Struts finos, muy finos y ultrafinos con polímero permanente o degradable ¿Cuál es la mejor combinación?

Thin, Very Thin, and Ultrathin Struts, with Permanent or Biodegradable Polymer… Which Is the Best Combination?

Results from the BIO-RESORT trial at three years, soon to be published in JACC Intv., show that, despite significant differences among stents as regards strut thickness and capability to reabsorb the polymer, there are no apparent safety or efficacy differences among devices. The aim of this study was to determine the three-year safety and efficacy

Top